(Q42242133)

19 October 2017

title

Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients (English)

1 reference

19 October 2017

0 references

1 reference

K G Julian

1

1 reference

19 October 2017

E Shattahi

series ordinal

2

1 reference

19 October 2017

J E Burg

series ordinal

3

1 reference

19 October 2017

J P Boehmer

series ordinal

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 November 2013

1 reference

Transplantation Proceedings

19 October 2017

published in

1 reference

19 October 2017

volume

45

1 reference

19 October 2017

issue

9

1 reference

19 October 2017

page(s)

3414-3417

1 reference

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab Induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.08.023

10.1016/J.TRANSPROCEED.2013.08.023

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference